|

Efbemalenograstim alfa Injection Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Henan Cancer Hospital1

Indications

  • Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in Febrile Neutropenia1
  • High Risk for Febrile Neutropenia of Chemotherapy Regimens1
  • Primary/Secondary Prevention1
  • Cancer1

Other1 trial

Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.